Share

Doximity Inc (DOCS.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

J.P. Morgan AI

The Titan FrameworkAI Thinker

Model rating

Strong Buy

5-Year Return Est.

+251.2%

DOCS.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

Doximity is a dominant Toll Collector trading at a severe discount due to growth-deceleration optics. The base case projects the company leveraging its 80 percent physician monopoly to maintain elite 89 percent gross margins and ~50 percent free cash flow margins. Immune to global energy shocks and tariffs, the company will direct its immense cash generation inward, maintaining an aggressive 8 to 12 percent annual buyback yield. This float cannibalization ensures robust EPS growth, triggering a systematic upward repricing as the market transitions from penalizing slower revenue growth to rewarding unassailable free cash flow generation and monopoly permanence.

Market saturation optics fade as massive share buybacks mathematically force EPS compounding.
The 40 percent R&D spike yields highly monetizable vertical AI tools embedded in the Dialer.
Geopolitical immunity attracts institutional capital fleeing global supply-chain and energy risks.
Hospital recruitment and pharma ad spending stabilize, proving the inelasticity of the physician network.
Implied multiple expands from ~20x to ~28x as the asset is reclassified from 'slow growth tech' to 'infrastructure monopoly.'

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-06-24	53.0
Observed price	2021-06-28	58.4
Observed price	2021-07-06	46.8
Observed price	2021-08-07	52.8
Observed price	2021-08-15	78.7
Observed price	2021-08-19	74.3
Observed price	2021-09-04	98.9
Observed price	2021-09-16	95.5
Observed price	2021-10-10	72.4
Observed price	2021-10-14	75.6
Observed price	2021-10-22	64.8
Observed price	2021-11-11	76.7
Observed price	2021-11-23	57.1
Observed price	2021-12-09	57.5
Observed price	2021-12-21	48.8
Observed price	2022-01-10	47.9
Observed price	2022-01-26	42.5
Observed price	2022-02-03	45.7
Observed price	2022-02-27	60.6
Observed price	2022-03-03	56.8
Observed price	2022-03-15	43.2
Observed price	2022-04-04	54.0
Observed price	2022-04-24	46.0
Observed price	2022-04-28	42.5
Observed price	2022-05-18	30.3
Observed price	2022-06-03	38.0
Observed price	2022-06-11	33.6
Observed price	2022-07-01	36.7
Observed price	2022-07-17	43.6
Observed price	2022-07-21	46.2
Observed price	2022-08-14	37.3
Observed price	2022-08-18	34.3
Observed price	2022-09-03	32.6
Observed price	2022-09-15	32.6
Observed price	2022-10-09	29.3
Observed price	2022-10-25	26.8
Observed price	2022-11-06	24.3
Observed price	2022-11-10	26.3
Observed price	2022-12-04	35.4
Observed price	2022-12-08	35.8
Observed price	2022-12-28	32.8
Observed price	2023-01-09	30.6
Observed price	2023-01-29	34.5
Observed price	2023-02-02	39.7
Observed price	2023-02-10	31.7
Observed price	2023-03-06	34.1
Observed price	2023-03-10	29.1
Observed price	2023-03-30	31.2
Observed price	2023-04-23	36.4
Observed price	2023-04-27	36.4
Observed price	2023-05-21	31.9
Observed price	2023-05-29	30.6
Observed price	2023-06-06	34.1
Observed price	2023-06-26	31.9
Observed price	2023-07-16	35.5
Observed price	2023-07-28	35.5
Observed price	2023-08-13	23.4
Observed price	2023-08-17	22.1
Observed price	2023-09-02	24.3
Observed price	2023-09-26	19.86
Observed price	2023-10-08	21.9
Observed price	2023-10-24	22.8
Observed price	2023-11-01	20.3
Observed price	2023-11-09	20.5
Observed price	2023-11-17	24.6
Observed price	2023-12-11	24.0
Observed price	2023-12-31	28.3
Observed price	2024-01-04	28.0
Observed price	2024-01-20	30.9
Observed price	2024-02-05	27.3
Observed price	2024-02-17	30.1
Observed price	2024-03-04	28.6
Observed price	2024-03-24	27.2
Observed price	2024-03-28	26.9
Observed price	2024-04-21	24.7
Observed price	2024-05-11	23.2
Observed price	2024-05-19	28.7
Observed price	2024-05-23	27.4
Observed price	2024-06-12	29.6
Observed price	2024-07-10	26.6
Observed price	2024-07-14	28.1
Observed price	2024-08-07	25.5
Observed price	2024-08-11	35.2
Observed price	2024-08-15	35.0
Observed price	2024-08-27	36.7
Observed price	2024-09-12	38.2
Observed price	2024-10-02	43.5
Observed price	2024-10-18	43.5
Observed price	2024-10-26	41.3
Observed price	2024-11-07	43.4
Observed price	2024-11-11	61.3
Observed price	2024-12-13	52.1
Observed price	2024-12-25	58.3
Observed price	2025-01-14	50.8
Observed price	2025-01-22	56.0
Observed price	2025-01-30	59.0
Observed price	2025-02-07	79.2
Observed price	2025-02-27	69.5
Observed price	2025-03-11	61.7
Observed price	2025-03-27	60.5
Observed price	2025-04-08	50.7
Observed price	2025-05-10	59.8
Observed price	2025-05-18	53.4
Observed price	2025-05-22	51.3
Observed price	2025-06-07	58.6
Observed price	2025-06-19	57.2
Observed price	2025-07-09	63.3
Observed price	2025-08-02	57.7
Observed price	2025-08-10	63.4
Observed price	2025-08-14	63.5
Observed price	2025-09-07	69.5
Observed price	2025-09-11	70.3
Observed price	2025-09-27	74.6
Observed price	2025-10-09	72.6
Observed price	2025-11-02	66.6
Observed price	2025-11-06	62.6
Observed price	2025-11-18	47.4
Observed price	2025-12-04	51.3
Observed price	2025-12-24	43.8
Observed price	2026-01-05	45.7
Observed price	2026-01-21	39.9
Observed price	2026-01-29	38.6
Observed price	2026-02-22	24.4
Observed price	2026-03-02	25.7
Observed price	2026-03-14	24.4
Observed price	2026-04-11	21.6
Observed price	2026-04-19	24.5
Observed price	2026-05-09	26.1
Observed price	2026-05-17	19.38
Observed price	2026-05-21	19.39
Observed price	2026-06-02	21.5
Observed price	2026-06-22	20.1
Observed price	2026-07-04	22.4
Observed price	2026-07-24	20.4
Observed price	2026-08-09	26.2
Observed price	2026-08-17	24.5
Observed price	2026-08-29	26.7
Observed price	2026-09-10	24.7
Observed price	2026-09-17	26.6
Observed price	2026-09-18	26.1
Published advisor forecast	2026-06-04	20.7
Published advisor forecast	2026-09-04	21.9
Published advisor forecast	2026-12-04	23.7
Published advisor forecast	2027-03-04	24.9
Published advisor forecast	2027-06-04	26.6
Published advisor forecast	2027-09-04	29.3
Published advisor forecast	2027-12-04	32.8
Published advisor forecast	2028-03-04	35.4
Published advisor forecast	2028-06-04	37.6
Published advisor forecast	2028-09-04	40.2
Published advisor forecast	2028-12-04	43.4
Published advisor forecast	2029-03-04	45.6
Published advisor forecast	2029-06-04	48.3
Published advisor forecast	2029-09-04	51.7
Published advisor forecast	2029-12-04	54.3
Published advisor forecast	2030-03-04	56.4
Published advisor forecast	2030-06-04	59.8
Published advisor forecast	2030-09-04	62.8
Published advisor forecast	2030-12-04	65.3
Published advisor forecast	2031-03-04	68.6
Published advisor forecast	2031-06-04	72.7

2. Scenarios & Signals

Bull case

The cannibalization strategy aligns perfectly with an aggressive digital health roll-up and successful AI monetization. Doximity acquires distressed health-tech assets for pennies, plugging them into its monopoly network to re-accelerate top-line growth above 20 percent. Meanwhile, a major EHR capitulates, granting Doximity seamless API access.

AI workflow integration becomes an indispensable, premium-tier subscription for 50 percent of users.
Distressed M&A targets yield immediate, highly accretive top-line expansion.
Pharmaceutical advertising budgets expand specifically for high-ROI digital channels.
Extreme float reduction creates a severe supply-side shortage of shares, driving exponential price appreciation.

Bear case

The 40 percent R&D surge fails to yield compelling AI products, while pharmaceutical companies drastically slash digital ad budgets under regulatory price controls. The network effect stagnates as newer, native-OS AI agents disintermediate Doximity's core utility, rendering the platform a stagnant, low-engagement directory.

regulations trigger a catastrophic, permanent contraction in pharma marketing spend.
Epic and Cerner successfully block Doximity from clinical workflows, capping product utility.
Heavy R&D spending structurally permanently degrades operating margins without ROI.
The stock is irrevocably branded a '' and suffers permanent multiple compression to single-digit P/E.

Current crowd narrative

The crowd sees an ex-COVID darling whose hyper-growth days are dead. They obsess over the deceleration from 66 percent top-line growth in 2022 to a pedestrian 13 percent today. The sell-side narrative screams 'value trap' and frets constantly over pharmaceutical marketing budget cuts under the new TrumpRx pricing regime. Anchored to an obsolete software-as-a-service multiple paradigm, the media and retail consensus completely ignore the balance sheet, viewing Doximity merely as a mature, niche social network highly vulnerable to advertising cyclicality.

Alpha-gap assessment

The variant perception is entirely structural: Doximity is not a software vendor; it is a Toll Collector on the US healthcare system. The market is mispricing the sheer gravity of its physician monopoly and the brutal math of its capital allocation. While the crowd cries over 13 percent top-line growth, they ignore an 11 percent buyback yield and 50 percent . This is a -cannibalization engine operating an unassailable chokepoint. Furthermore, its purely domestic revenue model provides absolute immunity to the geopolitical fragmentation and supply-chain blockades ravaging global equities today.

Convergence catalyst

The gap closes when Doximity reports an earnings quarter demonstrating flat or rising EPS entirely engineered by extreme share-count reduction, paired with early monetization metrics from its AI workflow products. When the market realizes the is vanishing while the cash flow remains intact, a severe mechanical re-rating will commence.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: moderate
Convergence-cycle position: capitulation

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Absolute Chokepoint Dominion	Doximity is a classic Toll Collector. By capturing the attention of over 80 percent of United States physicians, it holds a definitive, unassailable monopoly over the most lucrative professional demographic on Earth. It does not manufacture drugs or provide care; it taxes the pharmaceutical industry for the privilege of access. This deep network effect constitutes an impenetrable moat. As long as pharmaceutical companies require physician mindshare to drive prescribing behavior, they must pay Doximity's toll. This structural pricing power guarantees perpetual, high-margin revenue extraction regardless of broader software-sector cyclicality.	Not available%	+85.0%
Float Cannibalization Engine	The company is executing a ruthless, mathematically superior capital allocation strategy. Armed with untouchable 50 percent free cash flow margins and virtually zero debt, Doximity is aggressively devouring its own float, evidenced by a massive 11 percent trailing buyback yield. In a high-interest-rate, capital-scarce Warsh regime, this self-funding mechanism is a paramount advantage. By continually reducing the denominator of shares outstanding, Doximity engineers structural earnings-per-share growth even if top-line revenue decelerates. This is the hallmark of an empire transitioning from volatile growth to permanent, compounding dominance.	Not available%	+60.0%
Vertical AI Workflow Integration	Doximity is masking its next expansion wave behind a 40 percent year-over-year spike in Research and Development. The Titan recognizes this as the capitalization of Vertical AI. Utilizing their proprietary, closed-loop dataset of physician behavior and the ubiquitous Doximity Dialer, they are positioning to seamlessly embed agentic scribes, automated scheduling, and clinical workflow tools directly into the physician's pocket. Because they already own the distribution channel, customer acquisition costs are zero. This converts unmonetized utility into a highly scalable, premium recurring revenue stream.	Not available%	+50.0%
Geopolitical Insulation	While global equities are ravaged by Hormuz blockades, kinetic war in the Middle East, and sweeping tariffs, Doximity operates an entirely hermetically sealed domestic model. The US healthcare system cannot be offshored, and Doximity relies on zero imported physical commodities, energy-intensive logistics, or Asian semiconductor fab access for its daily operations. This absolute insulation from supply-chain fragmentation and raw-material inflation commands a massive safe-harbor premium. In an era of deglobalization, purely domestic digital monopolies are the ultimate defensive citadels.	Not available%	+40.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Pharma Marketing Budget Compression	The primary threat to Doximity's toll booth is the capital capacity of its payers. The TrumpRx initiatives and rising federal pressure on drug pricing constrain pharmaceutical gross margins. In response, legacy pharma empires are forced to rationalize marketing and commercialization budgets. While Doximity offers the highest return on investment for digital ad spend, a systemic contraction in overall pharmaceutical advertising outlays inevitably introduces friction to Doximity's top-line growth trajectory, shifting the narrative from hyper-growth to mature cyclicality.	Not available%	-25.0%
TOP LINE Saturation Optics	The empire has conquered its territory; now it must govern. Revenue growth has decelerated from a blistering 66 percent in 2022 to a pedestrian 13 percent in 2026. Because Doximity has already captured 80 percent of the total addressable physician market, organic user growth is mathematically capped. The market, addicted to software-as-a-service hyper-growth metrics, relentlessly penalizes this deceleration. Overcoming this friction requires pivoting the investor base from growth-chasing momentum tourists to yield-seeking permanent capital.	Not available%	-20.0%
R&d Margin Dilution	Building the next layer of the moat requires capital sacrifice. The company deliberately suppressed its latest net income print (down 12 percent year-over-year) via a massive 40 percent surge in Research and Development expenditures. While strategically necessary to combat AI disruption and launch new agentic tools, this aggressive spend dilutes near-term operating margins. In a market environment unforgiving of profitability deterioration, this optical drag repels algorithmic and short-term earnings-focused capital.	Not available%	-15.0%
Hospital Recruitment Freeze	A secondary pillar of Doximity's revenue stems from hospital and health system recruitment drives. As US healthcare systems face escalating labor costs, nursing shortages, and squeezed operating margins, many have instituted hard hiring freezes or dramatically reduced external recruiter spend. This cyclical vulnerability acts as a direct drag on Doximity's hiring-solutions segment, dampening forward revenue visibility until hospital unit economics structurally normalize.	Not available%	-15.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
EHR Integration Capitulation	If major Electronic Health Record oligopolies, such as Epic or Cerner, formally cave to physician demands and grant Doximity deep, frictionless API integration, Doximity transforms from a communications overlay into the primary operating system for physician workflow. This event instantly locks in the remaining holdouts, deepens the moat infinitely, and opens massive new software-as-a-service monetization channels previously blocked by EHR walled gardens.	35.0%	+40.0%
Aggressive Digital Health ROLL UP	Armed with a pristine balance sheet, zero debt, and massive cash generation, Doximity acts as a Conqueror, executing a ruthless roll-up of distressed digital health startups starved of venture capital in the high-rate regime. Acquiring subscale telehealth, scheduling, and diagnostic overlay tools for pennies on the dollar and plugging them into Doximity's 80 percent physician distribution network instantly generates massive accretion and re-accelerates growth.	45.0%	+30.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Pharma Advertising BAN	A populist, bipartisan regulatory strike against the pharmaceutical industry that strictly caps, heavily taxes, or outright bans digital direct-to-physician marketing. Because Doximity's core tollbooth relies on this specific capital flow, regulatory strangulation of pharma advertising would permanently impair the primary revenue engine, breaking the empire's fundamental economic model.	10.0%	-60.0%
Generative AI Disintermediation	Frontier AI models integrated directly into Apple iOS, Google Android, or native hospital EHRs successfully mimic Doximity's core utility (secure messaging, dialing, scheduling, and clinical search) without requiring a standalone application. If physicians find native operating-system AI agents superior, Doximity loses its daily active engagement, severely degrading the network effect that protects its dominion.	25.0%	-45.0%

Step-by-step forecast path

J.P. Morgan forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_e87f797f-3dfc-57ec-bac5-5b8e416248a9__sb5__20260605080350
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	+6.0%	21.94	Resilience in a volatile macro environment. The broad market digests geopolitical shocks, but Doximity's pure domestic exposure and aggressive buyback program provide a rigid floor, attracting defensive capital rotation.
2	December 4, 2026	+8.0%	23.70	Year-end capital reallocation favors high-FCF, zero-debt compounders. Early signals that the heavy R&D investment is translating into sticky AI workflow features begin to shift sentiment away from the 'slow growth' narrative.
3	March 4, 2027	+5.0%	24.88	Consolidation phase post-earnings. The float reduction becomes mathematically undeniable in the EPS print, but lingering concerns over hospital recruitment budgets keep a lid on explosive multiple expansion.
4	June 4, 2027	+7.0%	26.62	Momentum builds as pharmaceutical marketing budgets stabilize. The market recognizes Doximity's pricing power as pharma heavily concentrates remaining ad spend into the highest-ROI, physician-verified channel available.
5	September 4, 2027	+10.0%	29.29	A decisive inflection point. Successful deployment of vertical AI scribing tools triggers a wave of premium-tier subscriptions, re-accelerating top-line growth and validating the Titan thesis of dominion expansion.
6	December 4, 2027	+12.0%	32.80	The compounding mechanics take over. Shrinking share counts meet expanding margins as R&D costs normalize. Institutional investors aggressively re-rate the stock from a SaaS multiple to an infrastructure-monopoly premium.
7	March 4, 2028	+8.0%	35.42	Sustained execution. Management announces strategic tuck-in acquisitions using their fortress balance sheet, effortlessly plugging new capabilities into their 80-percent-penetrated physician network.
8	June 4, 2028	+6.0%	37.55	Normalizing growth cadence. The stock digests recent massive gains, trading tightly as the street models out the long-term cash flow trajectory under the new, larger, AI-augmented product suite.
9	September 4, 2028	+7.0%	40.18	Continued buyback pressure mechanically forces the share price upward. With the float significantly reduced from 2026 levels, even modest buying demand triggers outsized upward price movements.
10	December 4, 2028	+8.0%	43.39	End-of-year dominance. Doximity cements its status as the absolute chokepoint for US healthcare communications. Competitors have entirely failed to breach the network effect moat.
11	March 4, 2029	+5.0%	45.56	Steady state operations. Revenue growth settles into the mid-teens, but EPS grows in the high twenties due to the unrelenting float cannibalization engine and expanding operating leverage.
12	June 4, 2029	+6.0%	48.30	Further integration into hospital enterprise systems provides a new, sticky revenue layer. Switching costs deepen as Doximity becomes structurally embedded in daily clinical logistics.
13	September 4, 2029	+7.0%	51.68	The empire expands its toll extraction. Pricing power is exercised on pharmaceutical partners with zero churn; the ultimate proof of a dominant Toll Collector asset.
14	December 4, 2029	+5.0%	54.26	Year-end plateau. The multiple has fully normalized to reflect the monopoly status, meaning future returns track closely with the underlying free cash flow per share compounding rate.
15	March 4, 2030	+4.0%	56.43	Maturation phase begins. The focus shifts entirely to dividend initiation or accelerated special dividends, as cash generation outpaces even the most aggressive buyback capabilities.
16	June 4, 2030	+6.0%	59.82	A successful demographic transition. The platform proves essential to the next generation of medical residents, ensuring institutional permanence that outlasts the founding cohort.
17	September 4, 2030	+5.0%	62.81	Minor friction as broad healthcare regulatory reviews occur, but Doximity's position as a provider-utility rather than a cost-center keeps it shielded from populist antitrust ire.
18	December 4, 2030	+4.0%	65.32	Capital discipline remains flawless. The board continues to allocate every spare dollar to shareholder value, reinforcing the stock's status as a premier defensive holding.
19	March 4, 2031	+5.0%	68.59	Sustained compounding. Doximity's data repository regarding physician prescribing behavior and network interaction becomes an invaluable, un-replicable asset in the healthcare data economy.
20	June 4, 2031	+6.0%	72.70	Five years of absolute dominion realized. The share count has been decimated, free cash flow has structurally compounded, and the asset reigns as the undisputed Platform Lord of US healthcare professionals.

Advisor and configuration

Advisor: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release
Persona: J.P. Morgan
Archetype: The Titan
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete J.P. Morgan advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Warren Buffett — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.